Antiviral drug like Remdesivir and Favipiravir are not specifically used for Covid 19, but studies fount that there was some benefit of it, hence India has approved it for treatment.
The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel.
Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu.
It will be used for the treatment of patients with mild to moderate Covid-19.
The price for one tablet will be Rs 103 and will be available as a 200 mg tablet at MRP Rs 3500 for a stripe of 34 tablets.
FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19.
The medicine is prescription based with recommended dose being 1800 mg twice on day one, followed by 800 mg twice daily up to 14 days.
This drug was already being used in many countries for influenza. They have been using it in covid 19 treatment as well.
Antiviral drug like Remdesivir and Favipiravir are not specifically used for Covid 19, but studies fount that there was some benefit of it, hence India has approved it for treatment.
The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel.
The firm received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
The company hopes that the availability of an effective treatment such as FabiFlu will considerably help to reduce the pressure.
The approval's restricted use entails responsible medication usage where every patient must have signed informed consent before treatment initiation
Favipiravir can be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID-19 symptoms.
Favipiravir has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases.
Glenmark pharmaceuticals was the first company in India to initiate phase three clinical trials on Favipiravir for COVID-19 patients in India.